Related references
Note: Only part of the references are listed.Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib
Ola Linden et al.
ACTA ONCOLOGICA (2009)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Response to imatinib plus sirolimus in advanced chordoma
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2009)
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
A. Oden-Gangloff et al.
BRITISH JOURNAL OF CANCER (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors
Keith M. Skubitz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Silvia Stacchiotti et al.
CLINICAL CANCER RESEARCH (2009)
Ewing's Sarcoma: Standard and Experimental Treatment Options
Vivek Subbiah et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2009)
Desmoid tumors: need for an individualized approach
Eelco de Bree et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications
Beatriz Llombart et al.
HISTOPATHOLOGY (2009)
Current treatment options in dermatofibrosarcoma protuberans
Doreen Lemm et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy
David T. Vistica et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2009)
T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense
Tiziana Negri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma
Hayriye V. Erkizan et al.
NATURE MEDICINE (2009)
Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors
Alexander J. F. Lazar et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Molecular pathobiology of gastrointestinal stromal sarcomas
Christopher L. Corless et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Systemic therapy for metastatic colorectal cancer current questions
Dan S. Zuckerman et al.
CANCER (2008)
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C. Heinrich et al.
CLINICAL CANCER RESEARCH (2008)
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab:: A fluorescent in situ hybridization study
Nicola Personeni et al.
CLINICAL CANCER RESEARCH (2008)
Dermatofibrosarcoma protuberans
Vassilios A. Dimitropoulos
DERMATOLOGIC THERAPY (2008)
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours
J. Lasota et al.
HISTOPATHOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes
A. Bheda et al.
ONCOGENE (2008)
Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report
Doreen Lemm et al.
ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG (2008)
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
J. -Y. Blay et al.
ANNALS OF ONCOLOGY (2008)
Angiogenesis-promoting gene patterns in alveolar soft part sarcoma
Alexander J. F. Lazar et al.
CLINICAL CANCER RESEARCH (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor
Satoru Yuzawa et al.
CELL (2007)
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition
Masumi Tsuda et al.
CANCER RESEARCH (2007)
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA
Jung-Sik Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibrornatosis
Stefano Signoron et al.
CLINICAL CANCER RESEARCH (2007)
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas
Elena Tamborini et al.
CLINICAL CANCER RESEARCH (2006)
Pigmented villonodular synovitis
William M. Mendenhall et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2006)
Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
B. Liegl et al.
HISTOPATHOLOGY (2006)
Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis
Elena Tamborini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
E. Tamborini et al.
ONCOGENE (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells
RB West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study
WG Goettsch et al.
EUROPEAN JOURNAL OF CANCER (2005)
Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies
PM Weinberger et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2005)
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor κB
T Morgan et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Familial gastrointestinal stromal tumor syndrome: Phenotypic and molecular features in a kindred
FP Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
AL Dewar et al.
BLOOD (2005)
Aggressive fibromatosis
WM Mendenhall et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2005)
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225
GA McArthur et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Biology of gastrointestinal stromal tumors
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dcrmatofibrosarcoma protuberans
K Mizutani et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions -: A sensitive and specific immunohistochemical assay
P Argani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Receptor activator of NF-κB ligand (RANKL) is expressed in chondroblastoma:: possible involvement in osteoclastic giant cell recruitment
L Huang et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2003)
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate
J Mace et al.
CANCER (2002)
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
RG Maki et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations
MC Heinrich et al.
HUMAN PATHOLOGY (2002)
Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad
JA Carney et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma -: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents
P Argani et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Cyclooxygenase-2: a novel target for cancer chemotherapy?
W Dempke et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2001)
Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement
A Greco et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25
M Ladanyi et al.
ONCOGENE (2001)
Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
M Miettinen et al.
VIRCHOWS ARCHIV (2001)
Share Paper
